撞击区块链（BFI）与CSIR-CDRI签署了协议，以加强生物医学研究并推动医疗保健创新

该合作是在BFI-BIOME虚拟网络计划下的，该计划旨在满足该国未满足的临床需求

Blockchain For Impact (BFI), a healthcare fund established during the second wave of the COVID-19 pandemic in India, has signed an agreement with CSIR-Central Drug Research Institute (CDRI) to bolster biomedical research and drive innovation in healthcare.

Impact Block链（BFI）是在印度第二次COVID-19大流行期间建立的医疗基金，已与CSIR-中心药物研究所（CDRI）签署了一项协议，以增强生物医学研究并推动医疗保健的创新。

The collaboration falls under the BFI-BIOME Virtual Network Program, which aims to address unmet clinical needs in the country, focusing on research in malaria, dengue, and metabolic diseases. The partnership seeks to forge new pathways for translational research that will shape the future of healthcare and revolutionize India's public health landscape.

该协作属于BFI-BIOME虚拟网络计划，该计划旨在满足该国未满足的临床需求，重点关注疟疾，登革热和代谢疾病的研究。该合作伙伴关系旨在为转化研究奠定新的途径，以塑造医疗保健的未来并彻底改变印度的公共卫生景观。

BFI, a catalyst funder within the global blockchain industry, works with partners to build multi-sector collaborations that create long-term, equitable solutions to strengthen India's strained healthcare infrastructure and support marginalized and vulnerable communities.

BFI是全球区块链行业中的催化剂资助者，与合作伙伴合作，建立多部门的合作，创建长期，公平的解决方案，以加强印度紧张的医疗保健基础设施，并支持边缘化和脆弱的社区。

BFI has also announced a partnership with the Translational Health Science and Technology Institute (THSTI) under the BFI-BIOME Virtual Network Program to accelerate translational research in vaccines, infectious diseases, diagnostics, and metabolic diseases. BFI said the collaboration aligns with the nation's Viksit Bharat (developed India) goal by 2047 and contributes to India's vision of becoming a global leader in biotechnology.

BFI还宣布了与BFI-BIOME虚拟网络计划下的转化健康科学技术研究所（THSTI）合作，以加速疫苗，传染病，诊断和代谢疾病的转化研究。 BFI表示，该合作与美国维克西特·巴拉特（Viksit Bharat）（开发的印度）到2047年的目标保持一致，并为印度成为生物技术的全球领导者的愿景做出了贡献。

BFI has been actively working with leading Indian institutions to drive advancements in healthcare in the world's most populous country. In 2024, it allocated over $150,000 over three years to support healthcare-focused startup initiatives at the Indian Institute of Technology Kanpur (IITK), renowned for its excellence in science and engineering education. This cooperation aims to develop innovative solutions to address critical challenges within India's healthcare system.

BFI一直在与领先的印度机构积极合作，以推动世界上人口最多的国家的医疗保健发展。 2024年，它在三年内分配了15万美元，以支持印度坎普尔理工学院（IITK）以医疗保健为中心的初创企业计划，以其在科学和工程教育方面的卓越表现而闻名。这种合作旨在开发创新的解决方案，以应对印度医疗保健系统内的关键挑战。

Moreover, BFI has committed $900,000 over three years to the Indian Institute of Technology Bombay, a leading institution in engineering and research, to accelerate biomedical research across the country. Furthermore, it partnered with the Indian Institute of Science (IISc) to fund select life sciences research projects led by IISc faculty, fostering further innovation in the field.

此外，BFI在三年内向印度技术研究所（Institute of Institute of Institute of Institute of Institute of Institute of Institute of Institute of Institute of Institute of Institute of Institute of Institute of Institute of Institute of Institute of Institute of Institute of Institute of Institute of Institute of Institute of Institute of Engineering and Research是一家领先的机构，以加速全国的生物医学研究。此外，它与印度科学学院（IISC）合作，为由IISC教师领导的精选生命科学研究项目提供资金，从而促进了该领域的进一步创新。

India's healthcare sector has been leading the way in adopting emerging technologies, like blockchain and artificial intelligence (AI), to improve patient care, streamline operations, and strengthen data security. Despite these advancements, managing patient data securely and efficiently remains a significant hurdle. Blockchain technology presents a promising solution, providing a secure and transparent platform for data management that helps prevent breaches by creating an immutable record.

印度的医疗保健部门一直在采用区块链和人工智能（AI）等新兴技术，以改善患者护理，简化操作并加强数据安全。尽管取得了这些进步，但可以安全有效地管理患者数据仍然是一个重大障碍。区块链技术提出了一个有希望的解决方案，为数据管理提供了一个安全透明的平台，该平台有助于通过创建不变的记录来防止违规。

Moreover, blockchain can facilitate seamless data sharing between pharmaceutical companies and researchers, enhancing the development of new therapies and treatments.

此外，区块链可以促进制药公司和研究人员之间的无缝数据共享，从而增强新疗法和治疗方法的发展。

In addition to strengthening data security, blockchain can facilitate seamless data exchange between pharmaceutical companies and researchers, accelerating the discovery of new therapies and treatments.

除了加强数据安全外，区块链还可以促进制药公司与研究人员之间的无缝数据交换，从而加快发现新疗法和治疗方法。

According to a report by PwC, the Bengal Chamber, and Medica Hospitals, “Globally, healthcare organizations have started reaping the benefits of blockchain technology in terms of its various applications, such as in health data management, health information exchange, provider credentialing and accreditation, and pharmaceutical supply chain management.”

根据普华永道，孟加拉商会和医疗医院的报告，“全球医疗机构已经开始在其各种应用方面收获区块链技术的好处和药品供应链管理。”

“[The] Adoption of blockchain technology by the Indian healthcare industry will happen over a period of time as the effectiveness and sustainability of each use case are currently under research and development. At the same time, healthcare organizations need to undertake the necessary planning activities before entering into blockchain-based partnerships and programs,” the report said.

“由于目前正在研究和开发中，印度医疗保健行业对区块链技术的采用将在一段时间内发生。同时，医疗组织需要在建立基于区块链的合作伙伴关系和计划之前进行必要的计划活动。”

India plans Bio-Artificial Intelligence hubs

印度计划生物界情报枢纽

India recently introduced the BioE3 (Biotechnology for Economy, Employment, and Environment) Policy, marking a significant milestone for the local biotechnology sector and reinforcing its potential to shape the economy, employment landscape, and environmental sustainability in the years to come.

印度最近引入了BIOE3（用于经济，就业和环境的生物技术）政策，标志着当地生物技术部门的重要里程碑，并增强了其在未来几年塑造经济，就业环境和环境可持续性的潜力。

The objective of the BioE3 Policy is to set forth a framework that ensures the adoption of cutting-edge advanced technologies and aligns innovative research to promote biomanufacturing.

BIOE3政策的目的是制定一个框架，以确保采用尖端的先进技术并结盟创新的研究以促进生物制造。

Biomanufacturing is closely tied to healthcare, as it leverages living organisms like cells and microorganisms to produce therapeutic drugs, vaccines, and diagnostic tools. This process is crucial in developing modern medical treatments, including monoclonal antibodies, proteins, and cell-based therapies, and plays a vital role in advancing healthcare through personalized medicine and targeted treatments.

生物制造与医疗保健密切相关，因为它利用细胞和微生物等生物体生产治疗药物，疫苗和诊断工具。该过程对于开发现代医疗治疗至关重要，包括单克隆抗体，蛋白质和基于细胞的疗法，并且在通过个性化医学和有针对性治疗的医疗保健方面起着至关重要的作用。

India's BioE3 Policy aims to accelerate the development of technologies for bio-based products and their commercialization by setting up BioEnablers, including Bio-Artificial Intelligence (bio-AI) hubs, foundries, and biomanufacturing hubs across the country.

印度的BIOE3政策旨在通过建立包括生物兵工智能（Bio-AI）枢纽，铸造厂和生物制造枢纽在内的生物启程器来加速基于生物产品的技术及其商业化的技术。

Bio-AI hubs will be set up to augment research and innovation for developing technologies for bio-based products across the identified thematic sectors and subsectors of biomanufacturing by powering data-driven research and AI-informed predictive analytics. The bio-foundries and biomanufacturing hubs will focus on establishing infrastructure to scale up technologies for bio-based products.

Bio-AI枢纽将通过为确定的主题扇区和生物制造的亚部门开发基于生物的产品的技术的研究和创新，通过为数据驱动的研究和AI知识的预测分析提供动力。生物基础和生物制造枢纽将着重于建立基础设施，以扩展基于生物的产品的技术。

According to Science and Technology Minister Jitendra Singh, India is among the top six bio-manufacturers in the world and has one of the most cost-effective and efficacy-based biomanufacturing and healthcare destinations.

根据科学和技术部长吉滕德拉·辛格（Jitendra Singh）的说法，印度是世界上六名生物制造商之一，并且是最具成本效率和基于功效的生物制造和医疗保健目的地之一。

“Prime Minister Narendra Modi has a vision for a healthy India with the elimination of communicable diseases and reduction in non

“总理纳伦德拉·莫迪（Narendra Modi